What Slowdown? Chinese Maker Splashing Big On Promotion To Bolster Prices, Growth
This article was originally published in PharmAsia News
Could the economic slowdown in China actually translate into opportunities for domestic drug makers? A recent filing for an initial public offering reveals at least one company is forging full speed ahead by spending big on promotion and planning to add over a thousand sales reps, as it looks to shore up product prices and move deeper into the county-level sector.
You may also be interested in...
Frank Zhang, co-founder and chair of the Hong Kong-listed Chinese biotech Genscript, parent of Nasdaq-listed cell therapy star, Legend Biotech, has been detained by Chinese authorities, along with four employees.
China releases technical requirements for foreign drug makers to register their chemical drugs in the country, and issues patent linkage details, which a legal expert says needs to be closely examined.
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.